FGFR2 Mutation Detection for TKI Resistance Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tyrosine kinase inhibitors (TKIs) face limitations in long-term efficacy due to the development of resistance, particularly in cancers with mutated fibroblast growth factor receptor (FGFR) tyrosine kinases, necessitating the identification of specific resistance profiles and mutation detection for effective therapeutic targeting.
Innovation Solution
A method for identifying tumor cells resistant to FGFR2 inhibitors by detecting specific mutation variants such as M536I, M538I, I548V, N550H, N550K, N550S, V565I, E566G, L618M, and Y770IfsX14, and using these variants to screen agents that induce tumor cell death or inhibit tumor growth, with a kit comprising reagents for detecting these variants to facilitate pharmaceutical composition administration and response determination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tyrosine kinase inhibitors are used to treat cancers with mutated FGFR tyrosine kinases, then initial treatment efficacy is improved, but long-term efficacy deteriorates due to development of resistance
Solution Approach 1:
The patent performs preliminary detection of FGFR2 mutation variants in tumor cells before initiating TKI therapy. By identifying resistant mutations (such as M536I, M538I, I548V, N550H, N550K, N550S, V565I, E566G, L618M, Y770IfsX14) in advance, the system can determine patient suitability for TKI treatment and avoid ineffective treatment scenarios, thereby maintaining long-term efficacy by selecting appropriate candidates before therapy begins
2Productivity
If TKI therapy is administered to tumor cells with FGFR2 mutations, then tumor growth inhibition is achieved, but treatment resistance develops over time
Solution Approach 1:
The patent establishes a feedback mechanism by detecting FGFR2 mutation variants in tumor cells and using this information to determine response to TKI therapy. The system monitors for resistant mutations and adjusts treatment strategies accordingly, providing feedback that prevents ineffective treatment and identifies patients who may develop resistance, thereby maintaining reliable tumor growth inhibition
3Measurement precision
If comprehensive mutation screening is performed to identify resistance profiles, then treatment precision is improved, but test complexity increases
Solution Approach 1:
The patent segments the FGFR2 kinase domain into specific regions of interest containing known resistance mutation sites (such as the gatekeeper region at position 565-566 and other conserved residues). By focusing the mutation screening assay on these specific segmented regions rather than the entire gene, the system achieves comprehensive resistance profile identification while reducing test complexity through targeted analysis of critical mutation hotspots
Data Source
AI summary
This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.